<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cells due to a t(8;14) chromosomal translocation c-myc is often placed in proximity to the Emu enhancer of the Ig locus and upregulated </plain></SENT>
<SENT sid="1" pm="."><plain>We demonstrated that in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells a <z:chebi fb="0" ids="48021">peptide nucleic acid</z:chebi> (<z:chebi fb="3" ids="48021">PNA</z:chebi>), complementary to intronic Emu sequences (PNAEmuwt), specifically blocks the expression of the c-myc oncogene under the Emu enhancer control and inhibits <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell growth in culture </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we investigated whether PNAEmuwt was also able to block <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in <z:mp ids='MP_0002536'>SCID</z:mp> mice inoculated with human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>After subcutaneous inoculum in mice <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells reproducibly form <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Both pre-treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells with PNAEmuwt before inoculum and <z:hpo ids='HP_0011010'>chronic</z:hpo> intravenous administration of PNAEmuwt to mice already inoculated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells selectively caused increased latency of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> appearance and decreased final <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> from PNAEmuwt-treated animals showed substantial areas of cell <z:mp ids='MP_0001651'>necrosis</z:mp> and of c-myc downregulation </plain></SENT>
<SENT sid="6" pm="."><plain>Inhibition of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> was specific and was not observed with PNAEmumut carrying sequence mutations and in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines where the translocated c-myc is not under the control of the Emu enhancer </plain></SENT>
<SENT sid="7" pm="."><plain>These data confirm the potential therapeutic value of <z:chebi fb="3" ids="48021">PNA</z:chebi> targeted to regulatory non-coding regions </plain></SENT>
</text></document>